Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

oral myeloma therapy

- PMLiVE

NICE International relaunches, will offer advisory services

Meets growing demand from global health and social care organisations

- PMLiVE

Takeda divests over-the-counter and prescription drugs to Stada for $660m

Japanese pharma said it has plans to divest $10bn in non-core assests

- PMLiVE

Provention Bio wins PRIME designation for type 1 diabetes prevention drug

Meanwhile J&J partnered Crohn's drug flops in phase 2

- PMLiVE

NICE considering re-evaluation of quality of life assessment

Will address concerns around the watchdog's methodologies

- PMLiVE

Vertex, NHS England and NICE finally reach agreement for Orkambi

Deal also includes Vertex’s other licensed cystic fibrosis medicines

- PMLiVE

Merck wins CHMP recommendation for Ebola vaccine

Has also been granted priority review by FDA

- PMLiVE

Takeda offloads select portfolio to Acino ahead of Shire takeover

Hopes to reduce debt before acquistion completion

- PMLiVE

NICE turns down Roche’s Tecentriq for triple-negative breast cancer

Will also not be included in the Cancer Drugs Fund

- PMLiVE

NICE delivers final ‘no’ for Novartis’ migraine treatment Aimovig

Blow to patients who have dubbed the treatment 'life-saving'

- PMLiVE

Takeda’s HAE drug Takhzyro backed by NICE

New treatment option for rare, hereditary disease

Biomarin

NICE approves BioMarin’s Brineura after initial setback

First treatment for rare disease

- PMLiVE

NICE backs NHS use of Novartis’ gene therapy Luxturna

First and only therapy for rare, inherited form of blindness

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links